These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 10435880

  • 1. Effects of cholinergic muscarinic blockade on growth hormone responses to growth hormone-releasing hormone in uraemic patients.
    Díez JJ, Iglesias P, Aguilera A, Bajo MA, Selgas R.
    Nephrol Dial Transplant; 1999 Jul; 14(7):1704-9. PubMed ID: 10435880
    [Abstract] [Full Text] [Related]

  • 2. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
    Díez JJ, Iglesias P, Selgas R, Bajo MA, Aguilera A.
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):587-93. PubMed ID: 11106919
    [Abstract] [Full Text] [Related]

  • 3. Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans.
    Broglio F, Gottero C, Benso A, Prodam F, Casanueva FF, Dieguez C, van der Lely AJ, Deghenghi R, Arvat E, Ghigo E.
    Clin Endocrinol (Oxf); 2003 Jan; 58(1):92-8. PubMed ID: 12519418
    [Abstract] [Full Text] [Related]

  • 4. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P, Isidro L, Leal-Cerro A, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [Abstract] [Full Text] [Related]

  • 5. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
    Díez J, Iglesias P, Sastre J, Méndez J, Selgas R, Gómez-Pan A.
    Nephron; 1996 Apr; 74(3):548-54. PubMed ID: 8938679
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
    Rigamonti AE, Marazzi N, Cella SG, Cattaneo L, Müller EE.
    J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
    [Abstract] [Full Text] [Related]

  • 7. Cholinergic involvement in the growth hormone releasing hormone-induced growth hormone release: studies in normal and acromegalic subjects.
    Massara F, Ghigo E, Demislis K, Tangolo D, Mazza E, Locatelli V, Müller EE, Molinatti GM, Camanni F.
    Neuroendocrinology; 1986 Feb; 43(6):670-5. PubMed ID: 3093909
    [Abstract] [Full Text] [Related]

  • 8. Effects of cholinergic blockade on nocturnal thyrotropin and growth hormone (GH) secretion in type I diabetes mellitus: further evidence supporting somatostatin's involvement in GH suppression.
    Goñi MJ, Monreal M, Goñi F, Sopena M, Gil MJ, Moncada E, Salvador J.
    Metabolism; 1997 Nov; 46(11):1305-11. PubMed ID: 9361690
    [Abstract] [Full Text] [Related]

  • 9. Radiation and neuroregulatory control of growth hormone secretion.
    Ogilvy-Stuart AL, Wallace WH, Shalet SM.
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
    [Abstract] [Full Text] [Related]

  • 10. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F, Fernandez T, Martinez T, Peñalva A, Peinó R, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [Abstract] [Full Text] [Related]

  • 11. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M, Bossoni S, Alí A, Doga M, Reimondo G, Milani G, Peretti P, Manelli F, Angeli A, Giustina A.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [Abstract] [Full Text] [Related]

  • 12. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M, Procopio M, Grottoli S, Oleandri SE, Razzore P, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [Abstract] [Full Text] [Related]

  • 13. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [Abstract] [Full Text] [Related]

  • 14. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E, Gianotti L, Arvat E, Ramunni J, Valetto MR, Broglio F, Rolla M, Cavagnini F, Müller EE.
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [Abstract] [Full Text] [Related]

  • 15. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG, Macfarlane P, Levitt NS, Millar RP.
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [Abstract] [Full Text] [Related]

  • 16. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J, Diaz MJ, Tresguerres JA, Arce V, Lima L.
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [Abstract] [Full Text] [Related]

  • 17. Effects of cholinergic muscarinic antagonist pirenzepine on GH response to GHRH 1-40 in patients with anorexia nervosa.
    Rolla M, Andreoni A, Belliti D, Ferdeghini M, Cristofani R, Müller EE.
    Endocrinol Exp; 1990 Mar; 24(1-2):195-204. PubMed ID: 2113857
    [Abstract] [Full Text] [Related]

  • 18. Evidence for integrity of the growth hormone/insulin-like growth factor-1 axis in patients with severe head trauma during rehabilitation.
    Bondanelli M, Ambrosio MR, Margutti A, Boldrini P, Basaglia N, Franceschetti P, Zatelli MC, Degli Uberti EC.
    Metabolism; 2002 Oct; 51(10):1363-9. PubMed ID: 12370860
    [Abstract] [Full Text] [Related]

  • 19. Increased growth hormone response to growth hormone releasing hormone induced by erythropoietin in uraemic patients.
    Cantalamessa L, Cremagnani L, Orsatti A, Vigna L, Buccianti G.
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):85-9. PubMed ID: 2004477
    [Abstract] [Full Text] [Related]

  • 20. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L, Maccario M, Lanfranco F, Ramunni J, Di Vito L, Grottoli S, Muller EE, Ghigo E, Arvat E.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.